Payment overview · 2025
General Payments
$922.95
43 reported records · 16 companies
Healthcare provider profile · identity verified
Dwayne C Miller, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COMANCHE, TX · NPI 1316957574
Verified facts
What the public records show
CMS Open Payments records show Dwayne C Miller, M.D. received $922.95 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $269.46 | 29.2% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $126.18 | 13.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $109.22 | 11.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.31 | 5.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.96 | 5.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $49.13 | 5.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.56 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.10 | 4.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.17 | 3.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.88 | 3.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.06 | 2.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.79 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.81 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.53 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $922.95 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $167.96 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $126.18 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $123.36 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $84.47 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.31 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $34.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.03 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 693 | 119 |
| Gabapentin | Gabapentin | 438 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 404 | 82 |
| Donepezil Hcl | Donepezil Hcl | 386 | 64 |
| Potassium Chloride | Potassium Chloride | 364 | 82 |
| Meloxicam | Meloxicam | 341 | 83 |
| Lisinopril | Lisinopril | 331 | 80 |
| Eliquis | Apixaban | 288 | 45 |
| Memantine Hcl | Memantine Hcl | 272 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 61 |
| Furosemide | Furosemide | 261 | 56 |
| Allopurinol | Allopurinol | 249 | 70 |
| Alprazolam | Alprazolam | 237 | 41 |
| Omeprazole | Omeprazole | 221 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 217 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 49 |
| Metformin Hcl | Metformin Hcl | 206 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 175 | 117 |
| Losartan Potassium | Losartan Potassium | 173 | 43 |
| Sertraline Hcl | Sertraline Hcl | 166 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 47 |
| Montelukast Sodium | Montelukast Sodium | 151 | 44 |
| Tramadol Hcl | Tramadol Hcl | 148 | 32 |
| Simvastatin | Simvastatin | 144 | 26 |
| Mirtazapine | Mirtazapine | 143 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 18 |
| Finasteride | Finasteride | 131 | 30 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 130 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 122 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 32 |
| Carvedilol | Carvedilol | 119 | 28 |
| Prednisone | Prednisone | 119 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 31 |
| Sucralfate | Sucralfate | 118 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | suppressed |
| Pregabalin | Pregabalin | 97 | 17 |
| Buspirone Hcl | Buspirone Hcl | 91 | 15 |
| Spironolactone | Spironolactone | 91 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 17 |
| Famotidine | Famotidine | 80 | 20 |
| Lorazepam | Lorazepam | 80 | 21 |
| Trazodone Hcl | Trazodone Hcl | 75 | 12 |
| Warfarin Sodium | Warfarin Sodium | 74 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 16 |
| Atenolol | Atenolol | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 13 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Methotrexate | Methotrexate Sodium | 63 | 18 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Risperidone | Risperidone | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Primidone | Primidone | 59 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Topiramate | Topiramate | 58 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 37 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 42 |
| Myrbetriq | Mirabegron | 50 | 13 |
| Promethazine Hcl | Promethazine Hcl | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 49 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Methocarbamol | Methocarbamol | 46 | 17 |
| Pentoxifylline | Pentoxifylline | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Ozempic | Semaglutide | 44 | 15 |
| Digoxin | Digoxin | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 12 |
| Mupirocin | Mupirocin | 40 | 32 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 17 |
| Metronidazole | Metronidazole | 33 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 19 |
| Mirabegron Er | Mirabegron | 29 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 18 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $922.95 · 43 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SKYCLARYS, The Cologuard Plus Collection Kit, UBRELVY, VYEPTI, Veozah, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error